Danaher Co. (NYSE:DHR) Shares Sold by Van Den Berg Management I Inc.

Van Den Berg Management I Inc. reduced its stake in Danaher Co. (NYSE:DHR) by 6.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 17,008 shares of the conglomerate’s stock after selling 1,155 shares during the quarter. Van Den Berg Management I Inc.’s holdings in Danaher were worth $3,904,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Howard Capital Management Group LLC lifted its position in shares of Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 48 shares in the last quarter. Tudor Financial Inc. acquired a new stake in Danaher during the 3rd quarter worth approximately $414,000. Anchor Investment Management LLC boosted its position in Danaher by 1.3% in the 3rd quarter. Anchor Investment Management LLC now owns 6,039 shares of the conglomerate’s stock valued at $1,679,000 after buying an additional 78 shares during the period. World Investment Advisors LLC grew its stake in shares of Danaher by 5.3% in the third quarter. World Investment Advisors LLC now owns 12,948 shares of the conglomerate’s stock worth $3,600,000 after acquiring an additional 648 shares in the last quarter. Finally, Arvest Bank Trust Division acquired a new stake in shares of Danaher in the third quarter valued at $254,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 2.3 %

Shares of DHR stock opened at $196.52 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The stock has a market cap of $140.45 billion, a PE ratio of 37.22, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. The business’s fifty day moving average is $201.21 and its 200-day moving average is $225.57. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. Equities analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a yield of 0.65%. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio is currently 24.85%.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. UBS Group decreased their price target on shares of Danaher from $275.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday. The Goldman Sachs Group decreased their price target on Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a report on Wednesday. Robert W. Baird dropped their price objective on Danaher from $231.00 to $225.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Barclays upped their price target on Danaher from $205.00 to $215.00 and gave the company an “overweight” rating in a report on Tuesday. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $264.40.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.